Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-28
2011-11-29
Hui, San-Ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08067441
ABSTRACT:
The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.
REFERENCES:
patent: 0 159 640 (1985-10-01), None
patent: 5-078322 (1993-03-01), None
patent: 9-012550 (1997-01-01), None
patent: 0189520 (2001-11-01), None
patent: WO 02/053138 (2002-07-01), None
patent: 20070031882 (2007-03-01), None
patent: WO 2007/031832 (2007-03-01), None
Stadler M, Bauch F, Henkel T, Mühlbauer A, Müller H, Spaltmann F, and Weber K, “Antifungal actinomycete metabolites discovered in a differential cell-based screening using a recombinant TOPO1 deletion mutant strain,” Archiv der Pharmazie, May 2001, 334(5), 143-147.
Klegeris A and McGreer PL, “Non-Steroidal Anti-Inflammaotry Drugs (NSAIDs) and Other Anti-Inflammatory Agents in the Treatment of Neurodegenerative Diseas,” Current Alzheimer Research, Jul. 2005, 2(3), 355-365.
Shindo K, Yamagishi Y, Okada Y, and Kawai H, “Collismycins A and B, novel non-steroidal inhibitors of dexamethasone-glucocorticoid receptor binding,” Journal of Antibiotics, Sep. 1994, 47(9), 1072-1074.
van De Waterbeemd H, Smith DA, Beaumont K, and Walker DK, “Property-based design: optimization of drug absorption and pharmacokinetics,” Journal of Medicinal Chemistry, Apr. 2001,44(9), 1313-1333.
Vippagunta SR, Brittain HG, and Grant D J, “Crystalline solids,” Advanced Drug Delivery Reviews, May 2001,48(1), 3-26.
Adis R&D Insight, “Collismycin A,” Adisinsight Accession No. 1998:4421, Apr. 7, 1995.
Adis R&D Insight, “Collismycin B,” Adisinsight Accession No. 1998:4426, Apr. 10, 1995.
Cristalli, G. et al., “2,2'-Bipyridyl-6-carboxamidoximes with potential antitumor and antimicrobial properties,” Farmaco, Edizione Scientifica, (1986) vol. 41, Nr:7, pp. 499-507.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11thedition, McGraw-Hill Publishers, 2006, p. 673.
Honer et al., “Glucocorticoid Receptor Antagonism by Cyproterone Acetate and RU486,” Molecular Pharmacology, (2003) vol. 63, No. 5, pp. 1012-1020.
Miner et al., “A Nonsteroidal Glucocorticoid Receptor Antagonist,” Molecular Endocrinology, (2003) vol. 17, No. 1, pp. 117-127.
Park, H.-R., et al., “Regulation of grp78 transcription by substances of microbial origin,” Society for Neuroscience Abstracts, (2001) vol. 27, No. 1, pp. 1486.
Park, H.-R. et al., “Versipelostatin, a novel GRP78/Bip molecular chaperone down-regulator of microbial origin,” Tetrahedron Letters, (2002) vol. 43, Nr:39, pp. 6941-6945.
Reines et al., “Rofecoxib, No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study,” Neurology, (Jan. 2004), vol. 62, pp. 66-71.
Rosen et al., “The Search for Safer Glucocorticoid Receptor Ligands,” Endocrine Reviews, (Published online Apr. 6, 2005), vol. 26, No. 3, pp. 452-464.
Tsuge, N. et al., “Novel antibiotics pyrisulfoxin A and B produced byStreptomyces californicus,” Journal of Antibiotics, (1999) vol. 52, Nr:5, pp. 505-507.
van Goal, W.A. et al., “Anti-inflammatory therapy in Alzheimer's disease: is hope still alive?” J. Neurol., (2003) vol. 250, pp. 788-792.
Adler et al., “Vitamin E treatment of tardive dyskinesia,” 1993, 50: pp. 1405-1407, Abstract only, Am J Psychiatry.
Alexandrova et al., “Oxidative Stress During the Chronic Phase After Stroke,” 2005, 1:39(3), pp. 297-316, Free Radical Biology & Medicine.
Allard et al., “Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV infected subjects,” Journal, Sep. 10, 1998, 12: pp. 1653-1659, Abstract only, AIDS.
Asimakis et al., “Postischemic Recovery of Contractile Function is Impaired in SOD2+/− but Not SOD1 +/− Mouse Hearts,” 2002, 105, pp. 981-986, Circulation.
Babcock et al., “Regulation of Mitochondrial Iron Accumulation by Yfh1p, a Putative Homolog of Frataxin,” Jun. 13, 1997, pp. 1709-1712, vol. 276, No. 5319, Science, Abstract only.
Barnes et al., “Nuclear FactorkB-A Pivotal Transcription Factor in Chronic Inflammatory Diseases”, Apr. 10, 1997, 336: pp. 1066-1071, The New England Journal of Medicine.
Baum et al., “HIV-1 infection in women is associated with severe nutritional deficiencies,”, Dec. 1, 1997, vol. 16, pp. 272-278, J Acquir Immune Defic Syndr Hum Retrovirol, Abstract only.
Beal et al., “Increased 3-Nitrotyrosine in Both Sporadic and Familial Amyotrophic Lateral Sclerosis,” Oct. 1997, pp. 644-654, vol. 42, Issue 4, Annals of Neurology, Abstract only.
Beal et al., “3-Nitropropionic Acid Neurotoxicity Is Attenuated in Copper/Zinc Superoxide Dismutase Transgenic Mice,” 1995, pp. 919-922, vol. 65, Issue 2, Journal of Neurochemistry, Abstract only.
Bjugstad et al., “Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia,” Jun. 8, 1998, pp. 349-357, 795, Brain Res., Abstract only.
Bo et al., “Induction of Nitric Oxide Synthase in Demyelinating Regions of Multiple Sclerosis Brains,” Nov. 1994, pp. 778-786, vol. 36, Issue 5, Annals of Neurology, Abstract only.
Bolaños et al., “Effect of Peroxynitrite on the Mitochondrial Respiratory Chain: Differential Susceptibility of Neurones and Astrocytes in Primary Culture,” 1995, pp. 1965-1972, vol. 64, Issue 5, Journal of Neurochemistry, Abstract only.
Boven et al., “Increased Peroxynitrite Activity in AIDS Dementia Complex: Implications for the Neuropathogenesis of HIV-1 Infection,” 1999, pp. 4319-4327, 162 (7), J. Immunol., The American Association of Immunologists.
Brodsky et al., “Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells,” 2002, pp. H2130-H2139, 283, American Journal Physiol Heart Circ Physiol.
Brown et al., “Amyotrophic Lateral Sclerosis: Recent Insights from Genetics and Transgenic Mice,” Mar. 10, 1995, pp. 687-692, vol. 80, Cell.
Brown et al., “Vitamin E, Lipids, and Lipid Peroxidation Products in Tardive Dyskinesia,” Jun. 15, 1998, pp. 863-867, vol. 43, Issue 12, Biological Psychiatry, Abstract only.
Browne et al., “Oxidative Damage and Metabolic Dysfunction in Huntington's Disease: Selective Vulnerability of the Basal Ganglia,” May 1997, pp. 646-653, vol. 41, Issue 5, Annals of Neurology, Abstract only.
Browne et al., “Oxidative Stress in Huntington's Disease,” Jan. 1999, pp. 147-163, 9 (1), Brain Pathology.
Bruijn, et al., “Elevated Free Nitrotyrosine Levels, but not Protein-bound Nitrotyrosine or Hydroxyl Radicals, Throughout Amyotrophic Lateral Sclerosis (ALS)-like Disease Implicate Tyrosine Nitration as an Aberrant in vivo Property of one Familial ALS-linked Superoxide Dismutase 1 Mutant,” Jul. 1997, pp. 7606-7611, vol. 94, Proc. Natl Acad. Sci. USA.
Butterworth et al., “Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum,” Jun. 30, 1998, pp. 49-53. vol. 87, Issue 1, Neuroscience, Abstract only.
Buttke et al., “Oxidative stress as a mediator of apoptosis,” Jan. 1994, pp. 7-10, vol. 15 (1), Immunol Today, Abstract only.
Buyse et al., “Idebenone treatment in Friedreich's ataxia Neurological, cardiac, and biochemical monitoring,” 2003, pp. 1679-1681, vol. 60, Neurology, Abstract only.
Calabrese et al., Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia, 2005, pp. 145-162, vol. 233, Issue 1-2, Journal of Neurological Sciences.
Carri et al., “Neurodegeneration in Amyotrophic Lateral Sclero
Baz Julia Perez
Cascon Mercedes Alonso
Chimeno Rosa Isabel Fernandez
Egea Paola Usan
Fernandez Antonio Medarde
Hui San-Ming
Instituto Biomar S.A.
King & Spalding LLP
Neuropharma, S.A.
Sonnenfeld Kenneth H.
LandOfFree
Use of collismycin and derivatives thereof as oxidative... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of collismycin and derivatives thereof as oxidative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of collismycin and derivatives thereof as oxidative... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4280999